Physician profile
Thomas E Mcknight
NPI 1679578538
$4,549.95
in general payments reported to CMS, 2019-2025
26 companies · $789 in 2025
The $789 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $295 · 2020: $206 · 2021: $876 · 2022: $805 · 2023: $721 · 2024: $858 · 2025: $789.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,368.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,367.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,672.59 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $549.35 | 2022-2025 | Ingrezza, Ongentys |
| Ucb, INC. | $534.35 | 2019-2021 | |
| Eisai INC. | $317.16 | 2021-2025 | |
| Axsome Therapeutics, INC. | $237.26 | 2023-2025 | Sunosi |
| Almatica Pharma LLC | $165.66 | 2021-2023 | Gralise |
| Lilly USA, LLC | $150.48 | 2019-2025 | Kisunla |
| Teva Pharmaceuticals USA, INC. | $145.32 | 2023-2025 | Austedo Xr, Austedo |
| Amgen INC. | $139.39 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $125.28 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $124.61 | 2019-2024 | |
| Genentech USA, INC. | $53.24 | 2025 | Ocrevus Zunovo |
| Biogen, INC. | $44.34 | 2021-2025 | Leqembi |
| Arbor Pharmaceuticals, INC. | $37.60 | 2021 | |
| Alnylam Pharmaceuticals INC. | $36.35 | 2024 | Onpattro |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aucta Pharmaceuticals, INC. | $28.16 | 2025 | Motpoly Xr |
| Lundbeck LLC | $27.86 | 2022 | |
| Livanova USA, INC. | $23.96 | 2021-2022 | |
| Astrazeneca Pharmaceuticals Lp | $22.79 | 2025 | Wainua |
| Biohaven Pharmaceutical Holding Company Ltd. | $22.48 | 2022 | |
| Kyowa Kirin, INC. | $18.88 | 2024 | Nourianz |
| Novartis Pharmaceuticals Corporation | $16.93 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $15.51 | 2024 | Rexulti |
| Allergan, INC. | $14.69 | 2020 | |
| Supernus Pharmaceuticals, INC. | $13.55 | 2019 | |
| Impel Pharmaceuticals INC. | $12.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Mcknight listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.